{
  "id": 9299489,
  "title": "StandardX launches with £10M to expand isotope production for medicine and fusion",
  "url": "https://urgent.news/2026/09/23/standardx-launches-with-10m-to-expand-isotope-production-for-medicine",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-23T08:00:00.000Z",
  "source": {
    "name": "Tech.eu",
    "slug": "tech-eu",
    "url": "https://tech.eu/2026/09/23/standardx-launches-with-ps10m-to-expand-isotope-production-for-medicine-and-fusion/"
  },
  "original_language": "en",
  "account": "Deeptech firm StandardX has secured £10 million in initial capital to develop its accelerator-based isotope refinery and boost production of scarce isotopes for medical and energy applications. The seed round was spearheaded by Vsquared Ventures and East X Ventures, with additional backing from firstminute capital, UKI2S, Brevan Howard Macro Venture and Geometry. Founded in 2025 by nuclear engineers Richard Pearson (CEO) and Ross Allen (CTO), the startup aims to create an isotope refinery capable of manufacturing a diverse range of isotopes at commercial scale. StandardX’s mission is to establish a more dependable European supply chain for vital rare materials, addressing the reliance on a few aging facilities with limited output. The company's proprietary accelerator technology seeks to replace specialized isotope production infrastructure with a versatile platform for mass manufacturing various isotopes from a standard industrial setup. This system enables distributed production, allowing isotope creation closer to end-use locations. Initially, StandardX will concentrate on isotopes crucial for cancer diagnosis and treatment, such as those needed for targeted alpha therapies. The firm plans to deliver its inaugural isotopes to a medical research partner in 2027. The technology also supports the production of isotopes currently used by hospitals and those essential for emerging treatments, some of which are presently inaccessible at scale. Isotopes play a pivotal role in propelling innovation across multiple sectors, but they all grapple with supply constraints, with cancer medicine facing acute shortages affecting patients today and hindering progress in developing next-generation treatments. This issue is expected to worsen, with cancer cases projected to rise by 67% by 2050. Pearson stated, \"We're building the platform the world needs to tackle this challenge.\" StandardX intends to apply the same accelerator platform to generate isotopes for other industries, including tritium, a fuel utilized in fusion energy. The company has entered partnerships with fusion developers to manufacture tritium as they strive to bring fusion power to the grid. The seed funding will finance team expansion, secure StandardX's first industrial site in London and advance the design and construction of its first accelerator-based isotope refinery. The company also intends to commence pilot isotope production and distribution to a medical collaborator in 2027, preceding industrial-scale production from 2029.",
  "summary": "Deeptech company StandardX has raised £10million in seed funding to develop its accelerator-based isotope refinery andincrease production of rare isotopes used in medicine and energy. The round wasled...",
  "key_points": [
    "StandardX raises £10M to develop accelerator-based isotope refinery",
    "Company aims to create versatile platform for mass manufacturing isotopes",
    "Initial focus on isotopes for cancer treatment and fusion energy applications"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}